vanoxerine (GBR 12909)
/ Laguna Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
48
Go to page
1
2
November 23, 2025
Effect of morphine dependence and withdrawal on operant social interaction in male and female rats.
(PubMed, Drug Alcohol Depend)
- "Based on the literature, we also tested if a kappa opioid receptor (KOR) antagonist (LY2456302) and serotonin and dopamine reuptake inhibitors (fluoxetine and GBR12909), would independently reverse the effect of morphine exposure on social self-administration. Opioid dependence, but not withdrawal, decreased operant social interaction and food self-administration in male and female rats. This effect appears independent of KOR, serotonin, or dopamine signaling."
Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry
November 20, 2025
Glutathione deficiency and disturbances of sulfur homeostasis in the pathophysiology of schizophrenia
(PubMed, Postepy Biochem)
- "In one of the recently developed rat’s neurodevelopmental model, schizophrenic-like changes were induced by administration of buthioninesulfoximine (BSO) - an inhibitor of glutathione synthesis and a dopamine reuptake inhibitor - the compound GBR 12909 during the developmental period...The usefulness of the developed model was tested by the effect of the antipsychotic drug aripiprazole and N-acetylcysteine...At the biochemical level, both drugs significantly reduced the elevated concentration of bound sulfane sulfur in the hippocampus of model rats. Recent studies indicate that in the neurodevelopmental pathophysiology of schizophrenia, disturbances in the homeostasis of sulfur compounds play an important role, which are corrected by the action of drugs."
Journal • Review • CNS Disorders • Psychiatry • Schizophrenia
October 27, 2025
Unveiling conformation-selective regulation of the norepinephrine transporter.
(PubMed, Cell)
- "Through cryo-electron microscopy analysis of NET complexes with levomilnacipran, vanoxerine, and vilazodone, we identify a previously undefined allosteric site within NET's inner vestibule that enables conformation-selective regulation. Moreover, our structural identification of inhibitor occupancy at this conformation-selective site defines a mechanistic framework for targeted therapeutic intervention. These findings advance our understanding of NET allosteric modulation, providing a structure-guided framework for developing next-generation antidepressants targeting the inward-open conformation of NET for the treatment of neuropsychiatric disorders."
Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Psychiatry
September 10, 2025
Assessing adult zebrafish despair-like behaviors in the small vertical cylinder immobility test (VCIT).
(PubMed, J Neurosci Methods)
- "VCIT is sensitive to various stress-related manipulations and their bidirectional pharmacological modulation, hence emphasizing the growing relevance and potential of zebrafish in advancing neuropsychiatric research and identifying innovative treatments for neuropsychiatric disorders."
Journal • CNS Disorders • Depression • Mental Retardation • Psychiatry
August 27, 2025
Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential.
(PubMed, J Cardiovasc Dev Dis)
- "These findings demonstrate that nonclinical cardiac NAMs can recapitulate clinical outcomes, including detection of vanoxerine-induced delayed repolarization and proarrhythmic effects. Moreover, this work provides a foundation to evaluate the safety and efficacy of novel compounds to reduce the dependence on animal studies."
Journal • Cardiovascular
May 03, 2025
N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia.
(PubMed, Pharmacol Biochem Behav)
- "The schizophrenia-like behavior was induced in Sprague-Dawley male pups in the neonatal days p5-p16 by repeated administration of the glutathione synthesis inhibitor L-butionine-(S,R)-sulfoximine (BSO) given together with the dopamine reuptake inhibitor 1-[2-[Bis-4(fluorophenyl)methoxy]ethyl]-4-3-(3-phenylpropyl) (GBR 12909)...Moreover, repeated co-treatment with low doses of ARI with NAC also reversed schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. The above results indicated that NAC enhanced the action of ARI in the used neurodevelopmental rat model of schizophrenia, and the mechanism of action of the used drugs in this model is discussed."
Journal • Preclinical • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia
February 20, 2025
Hippocampal long-term potentiation is modulated by exercise-induced alterations in dopaminergic synaptic transmission in mice selectively bred for high voluntary wheel running.
(PubMed, Restor Neurol Neurosci)
- "The increased hippocampal LTP seen in HR mice with wheel access may be related to alterations in dopaminergic synaptic transmission that underlie the neurophysiological basis of hyperactivity, motor disorders, and/or motivation."
Journal • Preclinical • CNS Disorders
October 24, 2024
The dopamine transporter inhibition using GBR 12909 as a novel pharmacological tool to assess bipolar disorder-like neurobehavioral phenotypes in zebrafish.
(PubMed, Behav Brain Res)
- "We also emphasize the well-conserved DA-mediated signaling in zebrafish and the early expression of dopaminergic biomarkers in the brain, especially focusing on dopamine transporter (DAT), the main target of GBR 12909. Finally, we discuss potential advantages and limitations in the field, the perspectives of using GBR 12909 in BD research, and how distinct validation criteria (i.e., face, predictive, and construct validity) can be assessed in translational approaches using zebrafish-based models."
Journal • Review • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry
October 15, 2024
Exploration of vanoxerine analogues as antibacterial agents.
(PubMed, J Antibiot (Tokyo))
- "The most active compound displayed reduced inhibitory activity against the known human target of vanoxerine, the dopamine transporter. This work has identified a promising analogue, which could provide a starting point for further medicinal chemistry and drug development efforts to target mycobacteria."
Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
August 08, 2024
Dopamine reuptake and inhibitory mechanisms in human dopamine transporter.
(PubMed, Nature)
- "Here we report structures of the human dopamine transporter in its apo state, and in complex with the substrate dopamine, the attention deficit hyperactivity disorder drug methylphenidate, and the dopamine-uptake inhibitors GBR12909 and benztropine. Unlike the outward-facing state, which is stabilized by cocaine, GBR12909 and benztropine stabilize the dopamine transporter in the inward-facing state, revealing previously unseen drug-binding poses and providing insights into how they counteract the effects of cocaine. This study establishes a framework for understanding the functioning of the human dopamine transporter and developing therapeutic interventions for dopamine transporter-related disorders and cocaine addiction."
Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry
May 26, 2024
Subcutaneous administration of a novel TRPM8 antagonist reverses cold hypersensitivity while attenuating the drop in core body temperature.
(PubMed, Br J Pharmacol)
- "We achieve therapeutic efficacy with subcutaneous administration of a novel TRPM8 antagonist that attenuates deleterious influences on CBT, a side effect that has largely prevented the translation of TRPM8 as a target."
Journal • Immunology • Neuralgia • Oncology • Pain • TRPM8 • TRPV1
February 14, 2024
Repurposing the dopamine transporter antagonist vanoxerine to treat colorectal cancer.
(PubMed, Nat Cancer)
- No abstract available
Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
February 14, 2024
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors.
(PubMed, Nat Cancer)
- "Antagonizing DAT also enhanced tumor lymphocytic infiltration by activating endogenous transposable elements and type-I interferon response. Our study unveils the direct implication of the DAT-G9a axis in the maintenance of CSC populations and an approach to improve antitumor immune response in colon tumors."
Cancer stem • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
February 08, 2024
The influence of acute dopamine transporter inhibition on manic-, depressive-like phenotypes and brain oxidative status in adult zebrafish.
(PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
- "Depending on the dose, GBR 12909 also decreased SOD activity and TBARS levels, as well as increased GR activity and NPSH content. Collectively, our novel findings show that a single GBR 12909 administration evokes neurobehavioral changes that recapitulate manic- and depressive-like states observed in rodents, fostering the use of zebrafish models to explore BD-like responses in translational neuroscience research."
Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry
January 23, 2024
Cortical and Striatal Astrocytes of Neonatal Rats Display Distinct Molecular and Pharmacological Characteristics of Dopamine Uptake.
(PubMed, Int J Mol Sci)
- "The inhibition of DA uptake by the DAT inhibitor, GBR12909, and NET inhibitors, desipramine and nortriptyline, impeded DA uptake in striatal astrocytes more than in cortical astrocytes. Haloperidol, a DA receptor antagonist, and L-DOPA, a DA precursor, did not induce significant alterations in transporter mRNA expression. These findings underscore the intricate and region-specific mechanisms governing DA uptake in astrocytes, emphasizing the need for continued exploration to unravel the nuanced dynamics of astrocytic involvement in the DA tripartite synapse."
Journal • Preclinical
January 22, 2024
Impaired monoamine neural system in the mPFC of SHRSP/Ezo as an animal model of attention-deficit/hyperactivity disorder.
(PubMed, J Pharmacol Sci)
- "Methylphenidate (dopamine (DA) and noradrenaline (NA) reuptake inhibitor) and desipramine (NA reuptake inhibitor) improved LTP formation defects in the mPFC of SHRSP/Ezo, suggesting that NA or both DA and NA are required for improvement of impaired LTP...GBR-12909 (DA reuptake inhibitor) increased mPFC DA in WKY/Ezo but had no effect in SHRSP/Ezo...Meanwhile, basal DA levels in the mPFC of SHRSP/Ezo were paradoxically decreased. These results suggest that functional changes in the DA and NA neural system in the frontal lobe are involved in the pathology of ADHD."
Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Mental Retardation • Psychiatry
September 02, 2023
Development and validation of an automated microfluidic perfusion platform for parallelized screening of compounds in vitro.
(PubMed, Basic Clin Pharmacol Toxicol)
- "The platform was able to produce the expected releasing (D-Amphetamine, p-Chloroamphetamine) or inhibiting (GBR12909, paroxetine) profiles for the two transporters. Reduction of manual operation and introduction of automated flow control enabled the implementation of stronger standardized protocols and the possibility to obtain higher throughput by increasing parallelization."
Journal • Preclinical • Behavior Disorders • Psychiatry
October 28, 2023
Implications for Combination Therapy of Selective Monoamine Reuptake Inhibitors on Dopamine Transporters.
(PubMed, Biomedicines)
- "Here, to examine whether combination treatments of selective reuptake inhibitors have synergistic effects, the pharmacological properties of DAT, NET, and SERT were investigated using the selective inhibitors of each transporter, which are vanoxerine, nisoxetine, and fluoxetine, respectively. The homology models of DAT suggested a potential secondary inhibitor binding site that affects inhibition in an allosteric manner. These findings imply that the use of combination therapy with monoamine reuptake inhibitors should be approached cautiously, as antagonistic effects may occur."
Combination therapy • Journal
October 08, 2023
Dopamine in the nucleus accumbens shell controls systemic glucose metabolism via the lateral hypothalamus and hepatic vagal innervation in rodents.
(PubMed, Metabolism)
- "We show that sNAc dopaminergic signaling modulates hepatic glucose metabolism through GABAergic inputs to glutamatergic LHA cells and hepatic vagal innervation. This demonstrates that striatal control of glucose metabolism involves a dopaminergic sNAc-LHA-liver axis and provides a potential explanation for the effects of dopamine agonists and antagonists on glucose metabolism."
Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • DRD1
August 30, 2023
Treatment with aripiprazole and N-acetylcysteine affects anaerobic cysteine metabolism in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia.
(PubMed, FEBS J)
- "The schizophrenia-type changes were induced in Sprague-Dawley rats by repeated administration of the glutathione synthesis inhibitor L-butionine-(S,R)-sulfoximine in combination with the dopamine reuptake inhibitor GBR 12909 in the early postnatal period. The studied drugs significantly reduced the level of bound sulfane sulfur and the expression of tested enzymes. The reduction in bound sulfane sulfur level coincided with the attenuation of exploratory behavior, suggesting that modulation of anaerobic cysteine metabolism in the hippocampus may have therapeutic potential in schizophrenia."
Journal • Preclinical • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia
August 17, 2023
Neural targets of the enteric dopaminergic system in regulating motility of rat proximal colon.
(PubMed, Pflugers Arch)
- "In isolated segments of the rat proximal colon, the dopamine reuptake inhibitor GBR 12909 (GBR) causes a dilatation, while the D-like receptor antagonist SCH 23390 (SCH) induces a tonic constriction, suggesting that neurally released dopamine tonically stimulates enteric inhibitory efferent neurons...GBR (1 μM)-induced dilatations of colonic segments were prevented by SCH (5 μM), L-nitro arginine (L-NA; 100 μM), a nitric oxide synthase inhibitor, or tetrodotoxin (0.6 μM)...Enteric dopaminergic neurons appear to project to nitrergic neurons to dilate the proximal colon by activating neuronal D-like receptors. In addition, constitutively activated D-like receptors expressed in cells yet to be determined may provide a tonic inhibition on colonic constrictions."
Journal • Preclinical
May 01, 2023
Behavioral profile of adult zebrafish acutely exposed to a selective dopamine uptake inhibitor, GBR 12909.
(PubMed, J Psychopharmacol)
- "The dopamine transporter (DAT) is the main regulator of dopamine concentration in the extrasynaptic space. This behavioral profile generally parallels that of the DAT knockout rodents and zebrafish, and it overlaps with behavioral effects of other DAT-inhibiting drugs of abuse, such as cocaine and D-amphetamine. Collectively, our data support the utility of zebrafish in translational studies on DAT targeting neuropharmacology and strongly implicate DAT aberration as an important mechanisms involved in neurological and psychiatric diseases."
Journal • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry
April 29, 2023
Dopamine Transport Inhibition as an Animal Model of Bipolar Mania
(SOBP 2023)
- "These animal models are therefore invaluable tools for the analysis of neural contributors to bipolar mania-relevant behavior and the development of targeted therapeutics. Future work will explore potential mechanisms of GBR12909 effects, including the role of the dopamine-2 receptor."
Preclinical • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry
March 30, 2023
Drug Repositioning as a Therapeutic Strategy against Streptococcus pneumoniae: Cell Membrane as Potential Target.
(PubMed, Int J Mol Sci)
- "After four discrimination rounds, a set of seven compounds was finally selected, namely (i) clofilium tosylate; (ii) vanoxerine; (iii) mitoxantrone dihydrochloride; (iv) amiodarone hydrochloride; (v) tamoxifen citrate; (vi) terfenadine; and (vii) clomiphene citrate (Z, E). Moreover, all compounds but mitoxantrone caused a remarkable increase in the permeability of the bacterial membrane and share a common, minimal chemical structure consisting of an aliphatic amine linked to a phenyl moiety via a short carbon/oxygen linker. These results open new possibilities to tackle pneumococcal disease through drug repositioning and provide clues for the design of novel membrane-targeted antimicrobials with a related chemical structure."
Journal • Infectious Disease • Pneumococcal Infections • Pneumonia
February 26, 2023
The Role of the Dopamine System in Post-Stroke Mood Disorders in Newborn Rats.
(PubMed, Int J Mol Sci)
- "MCAO-induced depressive-like symptoms were reversed by the DA reuptake inhibitor GBR-12909. In conclusion, MCAO in newborn rats induced depressive-like symptoms and hyperactive behavior in the medium and long term, respectively, that were associated with alterations in the DA system."
Journal • Preclinical • Cardiovascular • CNS Disorders • Immunology • Mood Disorders • Psychiatry
1 to 25
Of
48
Go to page
1
2